Elan's Zonegran deal goes through
Elan has completed the sale of its North American and European interests in Zonegran to Eisai Inc. for €109m.
The pharmaceutical firm may also earn purchase payments of up to €92.24m when generic zonisamide is introduced in the US, which includes up to €21m on receiving marketing approval for Zonegran in Europe.